{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:35:20Z","timestamp":1756384520736},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Unitaid"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Many low- and-middle-income countries are disproportionately burdened by cervical cancer, resulting in high morbidity and mortality. HPV-DNA testing coupled with treatment with thermal ablation is a recommended screening and precancer treatment strategy, but not enough is known about how this can be effectively implemented in the context of integrated services. The (Scale Up Cervical Cancer Elimination by Secondary prevention Strategy, (SUCCESS) project is conducting a study to understand this approach, integrated into existing women\u2019s health services in Burkina Faso, Cote d\u2019Ivoire, Guatemala, and the Philippines (2020\u20132024).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A hybrid effectiveness-implementation type III mixed-methods observational study design is used to assess feasibility, acceptability, and costs of integrated service delivery in 10 sites per country, selected considering urban\/rural location, facility level, onsite\/offsite laboratories, and health services type. In each country, a sample size of 2227 women aged 25\u201349\u00a0years will be enrolled with about 20% being women living with HIV. The primary outcome is proportion of HPV positive women completing precancer treatment, if eligible, within three months of screening. Data collection and analysis includes; facility and client exit surveys, key informant and client interviews, registries and project records extractions, and costing data analysis. Analysis includes descriptive statistics, context description, thematic analysis, and document analysis. Quantitative analyses will be stratified by participant\u2019s HIV status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Recruitment of study participants started in April 2022 (Burkina Faso and C\u00f4te d\u2019Ivoire) and August 2022 (Guatemala and the Philippines). Enrolment targets for women screened, client exit, in-depth and key informant interviews conducted were reached in Burkina Faso and Cote d\u2019Ivoire in November 2022. Guatemala and Philippines are expected to complete enrolment by June 2023. Follow-up of study Participants 12-months post-treatment is ongoing and is expected to be completed for all countries by August 2024. In LMICs, integrating cervical cancer secondary prevention services into other health services will likely require specific rather than incidental recruitment of women for screening. Reconfiguration of laboratory infrastructure and planning for sample management must be made well in advance to meet induced demand for screening.<\/jats:p>\n                <jats:p><jats:italic>Trail Registration<\/jats:italic> ClinicalTrials.Gov ID: NCT05133661 (24\/11\/2021).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12978-023-01696-8","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T16:02:10Z","timestamp":1699891330000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Understanding integrated HPV testing and treatment of pre-cancerous cervical cancer in Burkina Faso, Cote d\u2019Ivoire, Guatemala and Philippines: study protocol"],"prefix":"10.1186","volume":"20","author":[{"given":"Mark","family":"Kabue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy L.","family":"Gauvreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nemdia","family":"Daceney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret Mary","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Shissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathurin","family":"Dodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Garces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Llave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blami","family":"Dao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diwakar","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"1696_CR1","unstructured":"World Health Organisation. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem and Its Associated Goals and Targets for the Period 2020\u20132030. 2; 2020."},{"key":"1696_CR2","unstructured":"World Health Organization. Analysis and Use of Health Facility Data: Guidance for HIV Programme Managers. 2018. https:\/\/www.who.int\/healthinfo\/FacilityAnalysisGuide_HIV.pdf."},{"issue":"2","key":"1696_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/QAD.0000000000001301","volume":"31","author":"HA Kelly","year":"2017","unstructured":"Kelly HA, Sawadogo B, Chikandiwa A, et al. Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV\/AIDS: effect of anti-retroviral therapy. AIDS. 2017;31(2):273\u201385. https:\/\/doi.org\/10.1097\/QAD.0000000000001301.","journal-title":"AIDS"},{"key":"1696_CR4","unstructured":"UICC. GLOBOCAN 2020: New Global Cancer Data.; 2020. https:\/\/www.uicc.org\/news\/globocan-2020-new-global-cancer-data."},{"key":"1696_CR5","first-page":"687","volume":"2006","author":"MH Mayrand","year":"2015","unstructured":"Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutl\u00e9e F. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med. 2015;2006:687\u201396.","journal-title":"N Engl J Med."},{"issue":"5","key":"1696_CR6","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ijc.21955","volume":"119","author":"J Cuzick","year":"2006","unstructured":"Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095\u2013101. https:\/\/doi.org\/10.1002\/ijc.21955.","journal-title":"Int J Cancer"},{"key":"1696_CR7","doi-asserted-by":"publisher","first-page":"a1754","DOI":"10.1136\/bmj.a1754","volume":"337","author":"J Dillner","year":"2008","unstructured":"Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754. https:\/\/doi.org\/10.1136\/bmj.a1754.","journal-title":"BMJ"},{"key":"1696_CR8","doi-asserted-by":"publisher","unstructured":"Carr S, Hespe C. Cervical cancer screening in low-income countries: a report on the implementation of cervical screening in Luzon, Philippines. J Glob Heal Reports. 2020:1\u20139. https:\/\/doi.org\/10.29392\/001c.14149.","DOI":"10.29392\/001c.14149"},{"key":"1696_CR9","unstructured":"World Health organization. Costing the National Response to Cervical Cancer\u202f: United Republic of Tanzania , 2020\u20132024.; 2020."},{"key":"1696_CR10","unstructured":"World Health Organization. Costing the National Strategic Plan on Prevention and Control of Cervical Cancer: Nigeria, 2017\u20132021; 2020."},{"issue":"3","key":"1696_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ijc.30695","volume":"141","author":"AK Mezei","year":"2017","unstructured":"Mezei AK, Armstrong HL, Pedersen HN, Campos NG, Mitchell SM, Sekikubo M, Byamugisha JK, Kim JJ, Bryan S, Ogilvie GS. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer. 2017;141(3):437\u201346. https:\/\/doi.org\/10.1002\/ijc.30695.","journal-title":"Int J Cancer"},{"key":"1696_CR12","unstructured":"Shissler T. Expanding HPV testing is essential for cervical cancer elimination goals\u2014UICC Blog, March, 2022. Accessed 05 Sept 2022 at https:\/\/www.uicc.org\/blog\/expanding-hpv-testing-essential-cervical-cancer-elimination-goals."},{"key":"1696_CR13","doi-asserted-by":"publisher","unstructured":"World Health organization. Cervical cancer Elimination. Geneva. https:\/\/doi.org\/10.1017\/9781108178594.030.","DOI":"10.1017\/9781108178594.030"},{"issue":"3","key":"1696_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","volume":"50","author":"GM Curran","year":"2012","unstructured":"Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217\u201326. https:\/\/doi.org\/10.1097\/MLR.0b013e3182408812.","journal-title":"Med Care"},{"issue":"2","key":"1696_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","volume":"38","author":"E Proctor","year":"2011","unstructured":"Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011;38(2):65\u201376. https:\/\/doi.org\/10.1007\/s10488-010-0319-7.","journal-title":"Adm Policy Ment Health"},{"key":"1696_CR16","unstructured":"RADAR Module 1\u2014Facility Survey FP Manual; accessed online at https:\/\/www.radar-project.org\/isaqoc. 31 Aug 2022."},{"key":"1696_CR17","unstructured":"World Health Organization. Improving data for decision-making: a toolkit for cervical cancer prevention and control programmes; 2018. Geneva: https:\/\/www.who.int\/ncds\/surveillance\/IDCCP-Toolkit-INTRODUCTION.pdf."}],"container-title":["Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-023-01696-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12978-023-01696-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-023-01696-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T16:06:03Z","timestamp":1699891563000},"score":1,"resource":{"primary":{"URL":"https:\/\/reproductive-health-journal.biomedcentral.com\/articles\/10.1186\/s12978-023-01696-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1696"],"URL":"https:\/\/doi.org\/10.1186\/s12978-023-01696-8","relation":{},"ISSN":["1742-4755"],"issn-type":[{"value":"1742-4755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"22 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consent was obtained from study participants and ethical clearance obtained from WHO ERC, JHSPH IRB and relevant bodies in each of the four study countries, as shown in Table InternalRef removed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}